Pulse Biosciences, INC

Pulse Biosciences announced its NANOPULSE-AF pivotal study for atrial fibrillation treatment has surpassed its enrollment midpoint, demonstrating strong site enthusiasm and rapid patient recruitment.

Pulse Biosciences announces plans to redeem outstanding common stock warrants, with a deadline for exercise set for July 13, 2026.

Pulse Biosciences' Board approved resolutions allowing TD Securities to sell common stock to affiliates, with potential purchases by key executives.

Pulse Biosciences announced Q1 2026 financial results and accelerated enrollment timelines for its pivotal cardiac catheter IDE trial, NANOPULSE-AF.

Pulse Biosciences announced positive late-breaking clinical data from its nPulse Cardiac Catheter System feasibility study, showing sustained high procedural success and efficiency in treating atrial fibrillation.

Pulse Biosciences released an updated investor presentation detailing progress on its nsPFA cardiac catheter and 2026 strategic objectives.

Pulse Biosciences reports first product revenue in Q1 2026, driven by Vybrance System, while advancing cardiac programs and managing operational expenses.

Pulse Biosciences reported increased net losses in Q3 2025 as it ramps up R&D and commercialization efforts for its NPS technology, securing first product revenue.

Pulse Biosciences reported a significant increase in net loss for Q2 2025 and H1 2025, driven by higher research and development and general and administrative expenses, despite advancing its novel nsPFA technology in cardiology and soft tissue ablation.

Pulse Biosciences reports a net loss of $16.8 million for Q1 2025, focusing on advancing its Nano-pulse Stimulation (NPS) technology in cardiology and soft tissue ablation.

Pulse Biosciences reports its Q3 2024 financial results, emphasizing advancements in its atrial fibrillation and soft tissue ablation programs, while continuing to operate without significant revenue.

Pulse Biosciences' Q2 2024 report highlights a continued focus on developing its nsPFA technology for atrial fibrillation and soft tissue ablation, with no revenue reported and ongoing operating losses.

Pulse Biosciences filed an amendment to its 2025 Annual Report to provide required disclosures regarding corporate governance, executive compensation, and director information.

Pulse Biosciences' 2025 Annual Report details significant progress in its Nano-pulse Stimulation (NPS) technology for atrial fibrillation and soft tissue ablation, alongside continued operating losses and plans for future capital raises.

Pulse Biosciences files an amendment to its 2024 Annual Report on Form 10-K to include information previously omitted regarding directors, executive officers, compensation, and corporate governance.

Pulse Biosciences' 2024 10-K filing highlights a strategic shift towards atrial fibrillation and soft tissue ablation, with ongoing clinical trials and regulatory clearances for its Nano-pulse Stimulation (NPS) technology.

Pulse Biosciences files its annual 10-K report, detailing executive compensation changes, financial performance, and risk factors, while also amending employment agreements for key executives.

Director Mahkam Zanganeh was granted stock options for 44,504 shares of Pulse Biosciences common stock.

Director Richard van den Broek was granted 38,423 stock options in Pulse Biosciences, Inc. as part of a compensation update.

Director Robert W. Duggan was granted 42,495 stock options in Pulse Biosciences, Inc. as disclosed in a recent SEC Form 4 filing.

Director Manmeet Singh Soni was granted 30,000 stock options in Pulse Biosciences, Inc. as part of a compensation package.

Director Maria Sainz was granted 33,793 stock options in Pulse Biosciences, Inc. as part of a compensation update.

Director and 10% owner Robert W. Duggan acquired 660,233 shares of Pulse Biosciences common stock through an at-the-market offering.

Pulse Biosciences announces its 2026 Annual Meeting of Stockholders, scheduled for June 11, 2026, to elect directors and ratify auditor appointments.

Pulse Biosciences, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on December 9, 2025, to vote on director elections, auditor ratification, executive compensation, and other corporate matters.

Pulse Biosciences, Inc. has filed definitive additional proxy soliciting materials with the SEC.

Pulse Biosciences will hold a special meeting to approve increasing its equity incentive plan by 2 million shares and ratify 1.1 million previously granted options.

Pulse Biosciences has filed a definitive proxy statement with the SEC.

Pulse Biosciences announces its 2024 annual meeting of stockholders to be held virtually on June 6, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Robert W. Duggan has increased his beneficial ownership in Pulse Biosciences, Inc. to approximately 71.9% following recent share acquisitions.